Anti-cancer potential of MAPK pathway inhibition in paragangliomas-effect of different statins on mouse pheochromocytoma cells.
To date, malignant pheochromocytomas and paragangliomas (PHEOs/PGLs) cannot be effectively cured and thus novel treatment strategies are urgently needed. Lovastatin has been shown to effectively induce apoptosis in mouse PHEO cells (MPC) and the more aggressive mouse tumor tissue-derived cells (MTT)...
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4028222?pdf=render |
id |
doaj-790ee855c92542cf96f77d52906cb93d |
---|---|
record_format |
Article |
spelling |
doaj-790ee855c92542cf96f77d52906cb93d2020-11-25T02:32:57ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0195e9771210.1371/journal.pone.0097712Anti-cancer potential of MAPK pathway inhibition in paragangliomas-effect of different statins on mouse pheochromocytoma cells.Stephanie M J FliednerTobias EngelNikoletta K LendvaiUma ShankavaramSvenja NöltingRobert WesleyAbdel G ElkahlounHendrik UngefrorenAngela OldoerpGary LampertHendrik LehnertHenri TimmersKarel PacakTo date, malignant pheochromocytomas and paragangliomas (PHEOs/PGLs) cannot be effectively cured and thus novel treatment strategies are urgently needed. Lovastatin has been shown to effectively induce apoptosis in mouse PHEO cells (MPC) and the more aggressive mouse tumor tissue-derived cells (MTT), which was accompanied by decreased phosphorylation of mitogen-activated kinase (MAPK) pathway players. The MAPK pathway plays a role in numerous aggressive tumors and has been associated with a subgroup of PHEOs/PGLs, including K-RAS-, RET-, and NF1-mutated tumors. Our aim was to establish whether MAPK signaling may also play a role in aggressive, succinate dehydrogenase (SDH) B mutation-derived PHEOs/PGLs. Expression profiling and western blot analysis indicated that specific aspects of MAPK-signaling are active in SDHB PHEOs/PGLs, suggesting that inhibition by statin treatment could be beneficial. Moreover, we aimed to assess whether the anti-proliferative effect of lovastatin on MPC and MTT differed from that exerted by fluvastatin, simvastatin, atorvastatin, pravastatin, or rosuvastatin. Simvastatin and fluvastatin decreased cell proliferation most effectively and the more aggressive MTT cells appeared more sensitive in this respect. Inhibition of MAPK1 and 3 phosphorylation following treatment with fluvastatin, simvastatin, and lovastatin was confirmed by western blot. Increased levels of CASP-3 and PARP cleavage confirmed induction of apoptosis following the treatment. At a concentration low enough not to affect cell proliferation, spontaneous migration of MPC and MTT was significantly inhibited within 24 hours of treatment. In conclusion, lipophilic statins may present a promising therapeutic option for treatment of aggressive human paragangliomas by inducing apoptosis and inhibiting tumor spread.http://europepmc.org/articles/PMC4028222?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Stephanie M J Fliedner Tobias Engel Nikoletta K Lendvai Uma Shankavaram Svenja Nölting Robert Wesley Abdel G Elkahloun Hendrik Ungefroren Angela Oldoerp Gary Lampert Hendrik Lehnert Henri Timmers Karel Pacak |
spellingShingle |
Stephanie M J Fliedner Tobias Engel Nikoletta K Lendvai Uma Shankavaram Svenja Nölting Robert Wesley Abdel G Elkahloun Hendrik Ungefroren Angela Oldoerp Gary Lampert Hendrik Lehnert Henri Timmers Karel Pacak Anti-cancer potential of MAPK pathway inhibition in paragangliomas-effect of different statins on mouse pheochromocytoma cells. PLoS ONE |
author_facet |
Stephanie M J Fliedner Tobias Engel Nikoletta K Lendvai Uma Shankavaram Svenja Nölting Robert Wesley Abdel G Elkahloun Hendrik Ungefroren Angela Oldoerp Gary Lampert Hendrik Lehnert Henri Timmers Karel Pacak |
author_sort |
Stephanie M J Fliedner |
title |
Anti-cancer potential of MAPK pathway inhibition in paragangliomas-effect of different statins on mouse pheochromocytoma cells. |
title_short |
Anti-cancer potential of MAPK pathway inhibition in paragangliomas-effect of different statins on mouse pheochromocytoma cells. |
title_full |
Anti-cancer potential of MAPK pathway inhibition in paragangliomas-effect of different statins on mouse pheochromocytoma cells. |
title_fullStr |
Anti-cancer potential of MAPK pathway inhibition in paragangliomas-effect of different statins on mouse pheochromocytoma cells. |
title_full_unstemmed |
Anti-cancer potential of MAPK pathway inhibition in paragangliomas-effect of different statins on mouse pheochromocytoma cells. |
title_sort |
anti-cancer potential of mapk pathway inhibition in paragangliomas-effect of different statins on mouse pheochromocytoma cells. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2014-01-01 |
description |
To date, malignant pheochromocytomas and paragangliomas (PHEOs/PGLs) cannot be effectively cured and thus novel treatment strategies are urgently needed. Lovastatin has been shown to effectively induce apoptosis in mouse PHEO cells (MPC) and the more aggressive mouse tumor tissue-derived cells (MTT), which was accompanied by decreased phosphorylation of mitogen-activated kinase (MAPK) pathway players. The MAPK pathway plays a role in numerous aggressive tumors and has been associated with a subgroup of PHEOs/PGLs, including K-RAS-, RET-, and NF1-mutated tumors. Our aim was to establish whether MAPK signaling may also play a role in aggressive, succinate dehydrogenase (SDH) B mutation-derived PHEOs/PGLs. Expression profiling and western blot analysis indicated that specific aspects of MAPK-signaling are active in SDHB PHEOs/PGLs, suggesting that inhibition by statin treatment could be beneficial. Moreover, we aimed to assess whether the anti-proliferative effect of lovastatin on MPC and MTT differed from that exerted by fluvastatin, simvastatin, atorvastatin, pravastatin, or rosuvastatin. Simvastatin and fluvastatin decreased cell proliferation most effectively and the more aggressive MTT cells appeared more sensitive in this respect. Inhibition of MAPK1 and 3 phosphorylation following treatment with fluvastatin, simvastatin, and lovastatin was confirmed by western blot. Increased levels of CASP-3 and PARP cleavage confirmed induction of apoptosis following the treatment. At a concentration low enough not to affect cell proliferation, spontaneous migration of MPC and MTT was significantly inhibited within 24 hours of treatment. In conclusion, lipophilic statins may present a promising therapeutic option for treatment of aggressive human paragangliomas by inducing apoptosis and inhibiting tumor spread. |
url |
http://europepmc.org/articles/PMC4028222?pdf=render |
work_keys_str_mv |
AT stephaniemjfliedner anticancerpotentialofmapkpathwayinhibitioninparagangliomaseffectofdifferentstatinsonmousepheochromocytomacells AT tobiasengel anticancerpotentialofmapkpathwayinhibitioninparagangliomaseffectofdifferentstatinsonmousepheochromocytomacells AT nikolettaklendvai anticancerpotentialofmapkpathwayinhibitioninparagangliomaseffectofdifferentstatinsonmousepheochromocytomacells AT umashankavaram anticancerpotentialofmapkpathwayinhibitioninparagangliomaseffectofdifferentstatinsonmousepheochromocytomacells AT svenjanolting anticancerpotentialofmapkpathwayinhibitioninparagangliomaseffectofdifferentstatinsonmousepheochromocytomacells AT robertwesley anticancerpotentialofmapkpathwayinhibitioninparagangliomaseffectofdifferentstatinsonmousepheochromocytomacells AT abdelgelkahloun anticancerpotentialofmapkpathwayinhibitioninparagangliomaseffectofdifferentstatinsonmousepheochromocytomacells AT hendrikungefroren anticancerpotentialofmapkpathwayinhibitioninparagangliomaseffectofdifferentstatinsonmousepheochromocytomacells AT angelaoldoerp anticancerpotentialofmapkpathwayinhibitioninparagangliomaseffectofdifferentstatinsonmousepheochromocytomacells AT garylampert anticancerpotentialofmapkpathwayinhibitioninparagangliomaseffectofdifferentstatinsonmousepheochromocytomacells AT hendriklehnert anticancerpotentialofmapkpathwayinhibitioninparagangliomaseffectofdifferentstatinsonmousepheochromocytomacells AT henritimmers anticancerpotentialofmapkpathwayinhibitioninparagangliomaseffectofdifferentstatinsonmousepheochromocytomacells AT karelpacak anticancerpotentialofmapkpathwayinhibitioninparagangliomaseffectofdifferentstatinsonmousepheochromocytomacells |
_version_ |
1724816534028681216 |